Fred Hutch's Gilliland optimistic about cancer cures; Report: Biosims market to jump to $20B;

@FierceBiotech: ICYMI yesterday: Baxalta sets sail with blockbuster ambitions for its growing pipeline. Article | Follow @FierceBiotech

@JohnCFierce: Trending yesterday: Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis. Article | Follow @JohnCFierce

@DamianFierce: Join us as we search for the Amar'e Stoudemire of immuno-oncology. Listen to FierceBiotech Radio | Follow @DamianFierce

> Fred Hutchinson Cancer Research president Dr. Gary Gilliland told an audience that "it is actually plausible that in 10 years we will have cures and therapies for most, if not all, human cancers." Story

> A new report from GBI research projects that the global biosimilars market will be worth $20 billion in 10 years' time. Report

> China's Guangxi Wuzhou Zhongheng Group is investing $52 million into Oramed . Story

Medical Device News

@FierceMedDev: Langer Lab company gets $5M in funding for drug-delivery device. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: Cynapsus' sublingual Parkinson's med for 'off' episodes progresses to PhIII. FierceDrugDelivery report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Analysts: Roche sale of diabetes diagnostics unit could be a long time coming. Article | Follow @EmilyWFierce

> GlySure gets CE mark for first continuous, intravascular glucose monitor for hospital use. More

> Novartis launches navigation app for visually disabled on Apple Watch. Story

Pharma News

@FiercePharma: California strikes down exemptions to vaccination requirements for schoolchildren. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here. | Follow @EricPFierce

@CarlyHFierce: Boehringer gets respiratory boost with batch of Spiolto nods in EU. News | Follow @CarlyHFierce

> Scientists dig up new evidence linking GSK's Pandemrix with narcolepsy. Item

> Eylea expected to keep delivering for Regeneron as Praluent starts to step up. Report

Vaccines News

> Study: Flublok is more effective than traditional flu shot. Item

> Actelion pours out $33M to create vaccine startup with Max Planck Society. News

> California strikes down exemptions to vaccination requirements for schoolchildren. Story

> Sanaria raises $48.5M from Equatorial Guinea, oil and gas companies to develop malaria vaccine. Article

> Cancer vaccines field to see sizable growth, report says. More

CRO News

> Quintiles and Quest unveil their clinical trials joint venture. Item

> GVK inks another R&D deal as it moves on from data scandal. Story

> Covance joins trial site group to speed up R&D. News

> PPD strings together a site network for pediatric trials. Article

> BioClinica expands in Europe with a focus on imaging. Report

Pharma Manufacturing News

> Sanofi to improve environmental impact of its manufacturing plants. Item

> Lonza expands New Hampshire plant to make Alexion products. News

> FDA warning letter lays out cross-contamination issues at Canada plant. Story

> Listen up, eardrop makers: FDA says get products approved or face prosecution. Article

> Biogen embarks on major manufacturing expansion. News

Pharma Asia News

> Stormy Australia hearings on transfer pricing by drug firms invoke Sergeant Schultz. Report

> China's Universal prices IPO at $447M as HKEx shows attraction to healthcare. Article

> India's Marksans Pharma buys U.S.-based Time-Cap, a trend in the making? More

> Australia's Prana Biotech touts Imagine PBT2 safety trial outcome in comeback bid. Story

> GSK's ViiV unit to work with China's Desano to make API of Tivicay for access use. Item

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.